3McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective cmnparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail, 2014, 16: 817-825.
4Packer M, McMurray JJ, Desai AS , et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131: 54-61.
5McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J, 2015, 36: 434-439.
6von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfimction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. Circ Heart Fail, 2015, 8: 71-78.
7Bavishi C, Messerli FH, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J, 2015, 36: 1967-1973.
8McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014, 371: 993 - 1004.
9Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin- angiotensin system inhibition for the treatment of heart failure. JACC Heart Failure, 2014, 2:663 - 670.
10McMurray J J, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impaet on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). EurJ Heart Fail, 2013, 15: 1062-1073.
